Loading...

Tewari, Krishnansu Sujata

TitleProfessor
InstitutionUniversity of California, Irvine
DepartmentObstetrics and Gynecology
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-8020
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Novel biologic markers of treatment resistance in locally advanced cervical carci
    NIH/NCI R21CA156032Jan 1, 2011 - Dec 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2018 Oct 05; JCO1800454. PMID: 30289732.
      View in: PubMed
    2. Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 Aug 31. PMID: 30177462.
      View in: PubMed
    3. Pfaendler KS, Liu MC, Tewari KS. Bevacizumab in Cervical Cancer: 5 Years After. Cancer J. 2018 Jul/Aug; 24(4):187-192. PMID: 30119082.
      View in: PubMed
    4. Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018 May 24. PMID: 29804638.
      View in: PubMed
    5. Longoria TC, Tewari KS. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Expert Opin Drug Metab Toxicol. 2018 May 16; 1-8. PMID: 29620474.
      View in: PubMed
    6. Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 Mar 15. PMID: 29550184.
      View in: PubMed
    7. Gordon C, Carmichael JC, Tewari KS. Oncofertility in the setting of advanced cervical cancer - A case report. Gynecol Oncol Rep. 2018 May; 24:27-29. PMID: 29845104.
      View in: PubMed
    8. Wolford JE, Tewari KS. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. Expert Opin Drug Discov. 2018 May; 13(5):445-457. PMID: 29463131.
      View in: PubMed
    9. Minion LE, Tewari KS. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018 Mar; 148(3):609-621. PMID: 29666026.
      View in: PubMed
    10. Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract. 2018; 5:1. PMID: 29318022.
      View in: PubMed
    11. Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res. 2018 Feb 15; 24(4):777-783. PMID: 29191972.
      View in: PubMed
    12. Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018 Jan; 118(2):162-170. PMID: 29182608.
      View in: PubMed
    13. Horowitz NS, Larry Maxwell G, Miller A, Hamilton CA, Rungruang B, Rodriguez N, Richard SD, Krivak TC, Fowler JM, Mutch DG, Van Le L, Lee RB, Argenta P, Bender D, Tewari KS, Gershenson D, Java JJ, Bookman MA. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2018 Jan; 148(1):49-55. PMID: 29174555.
      View in: PubMed
    14. Serna-Gallegos TR, LaFargue CJ, Tewari KS. THE ECSTACY OF GOLD Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab. Recent Pat Biotechnol. 2017 11 22. PMID: 29173192.
      View in: PubMed
    15. Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):396-401. PMID: 28935272.
      View in: PubMed
    16. Wolford JE, Tewari KS. Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology. J Gynecol Oncol. 2017 09; 28(5):e74. PMID: 28758380.
      View in: PubMed
    17. Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249. PMID: 28807367.
      View in: PubMed
    18. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663. PMID: 28756902.
      View in: PubMed
    19. Chan JK, Deng W, Higgins RV, Tewari KS, Bonebrake AJ, Hicks M, Gaillard S, Ramirez PT, Chafe W, Monk BJ, Aghajanian C. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):554-559. PMID: 28728751.
      View in: PubMed
    20. Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253. PMID: 28532857.
      View in: PubMed
    21. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun; 18(6):779-791. PMID: 28438473.
      View in: PubMed
    22. Minion LE, Tewari KS. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer. Expert Rev Anticancer Ther. 2017 Mar; 17(3):191-198. PMID: 27748633.
      View in: PubMed
    23. Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993. PMID: 27864921.
      View in: PubMed
    24. Tewari KS. Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. Gynecol Oncol Res Pract. 2016; 3:10. PMID: 28685778.
      View in: PubMed
    25. Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O'Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465. PMID: 27743738.
      View in: PubMed
    26. Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489. PMID: 27726923.
      View in: PubMed
    27. Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol. 2016 Nov; 143(2):294-301. PMID: 27542967.
      View in: PubMed
    28. Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016 Oct; 12(10):1247-53. PMID: 27485741.
      View in: PubMed
    29. Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2016 Jul 01; 34(19):2279-86. PMID: 27217446; PMCID: PMC4962710 [Available on 07/01/17].
    30. Alldredge JK, Tewari KS. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. Oncologist. 2016 05; 21(5):576-85. PMID: 27026677; PMCID: PMC4861362 [Available on 05/01/17].
    31. Liu FW, Tewari KS. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Curr Treat Options Oncol. 2016 Mar; 17(3):12. PMID: 26931795.
      View in: PubMed
    32. LaFargue CJ, Tewari KS. Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer. Recent Pat Biotechnol. 2016; 9(2):86-101. PMID: 26961668.
      View in: PubMed
    33. Monk BJ, Herzog TJ, Tewari KS. Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients. Curr Pharm Des. 2016; 22(30):4717-4728. PMID: 27145761.
      View in: PubMed
    34. Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ, Poveda A, Landrum LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH. Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clin Cancer Res. 2015 Dec 15; 21(24):5480-7. PMID: 26672085; PMCID: PMC4896296 [Available on 12/15/16].
    35. Hodeib M, Serna-Gallegos T, Tewari KS. A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. Future Oncol. 2015; 11(23):3113-31. PMID: 26597460.
      View in: PubMed
    36. Longoria TC, Tewari KS. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations. Drugs. 2015 Nov; 75(16):1853-65. PMID: 26474780.
      View in: PubMed
    37. Tewari KS. Clinical implications for cediranib in advanced cervical cancer. Lancet Oncol. 2015 Nov; 16(15):1447-1448. PMID: 26474520.
      View in: PubMed
    38. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016 Jan; 27(1):114-21. PMID: 26487588; PMCID: PMC4684156 [Available on 01/01/17].
    39. Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016 Jan; 214(1):22-30. PMID: 26212178.
      View in: PubMed
    40. Tewari KS, Eskander RN, Monk BJ. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3829-35. PMID: 26169965.
      View in: PubMed
    41. Wolford JE, Tewari KS. US FDA oncology drug approvals in 2014. Future Oncol. 2015; 11(13):1931-45. PMID: 26039742.
      View in: PubMed
    42. Liu FW, Cripe J, Tewari KS. Anti-angiogenesis therapy in gynecologic malignancies. Oncology (Williston Park). 2015 May; 29(5):350-60. PMID: 25979545.
      View in: PubMed
    43. Cripe J, Eskander R, Tewari K. Sentinel lymph node mapping of a breast cancer of the vulva: Case report and literature review. World J Clin Oncol. 2015 Apr 10; 6(2):16-21. PMID: 25866706; PMCID: PMC4390890.
    44. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun; 137(3):386-91. PMID: 25818403.
      View in: PubMed
    45. Minion LE, Bai J, Monk BJ, Robin Keller L, Ramez EN, Forde GK, Chan JK, Tewari KS. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol. 2015 Jun; 137(3):490-6. PMID: 25766118.
      View in: PubMed
    46. Eskander RN, Lynch HT, Brown SM, Wagman LD, Tewari KS. Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome. Gynecol Oncol Rep. 2015 Apr; 12:31-3. PMID: 26076155; PMCID: PMC4442652.
    47. Monk BJ, Miller DS, Tewari KS. Reply to W.A.A. Tjalma and J.S. Grossman. J Clin Oncol. 2015 Mar 10; 33(8):966. PMID: 25667286.
      View in: PubMed
    48. Krill LS, Tewari KS. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert Opin Pharmacother. 2015 Apr; 16(5):675-83. PMID: 25643984.
      View in: PubMed
    49. Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Method M, Michael H, Tewari KS. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015 Mar; 16(3):301-11. PMID: 25638326; PMCID: PMC4479218.
    50. Krill LS, Tewari KS. Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer. Clin Ther. 2015 Jan 01; 37(1):9-19. PMID: 25592088.
      View in: PubMed
    51. Eskander RN, Tewari KS. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Clin Ther. 2015 Jan 01; 37(1):20-38. PMID: 25592089.
      View in: PubMed
    52. Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol. 2015; 11(6):909-22. PMID: 25760973.
      View in: PubMed
    53. Tewari KS, Monk BJ. Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer. Clin Adv Hematol Oncol. 2014 Nov; 12(11):737-48. PMID: 25674713.
      View in: PubMed
    54. Eskander RN, Tewari KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. 2014 Nov; 6(6):280-92. PMID: 25364393; PMCID: PMC4206649.
    55. Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol. 2015 Apr; 212(4):468.e1-9. PMID: 25448522.
      View in: PubMed
    56. Eskander RN, Tewari KS. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Expert Rev Clin Pharmacol. 2014 Nov; 7(6):847-58. PMID: 25301678.
      View in: PubMed
    57. Gibson SJ, Tewari KS, Monk BJ, Chase DM. Updates on drug discovery in ovarian cancer. Gynecol Oncol Res Pract. 2014; 1:3. PMID: 27231556; PMCID: PMC4878024.
    58. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83. PMID: 25199754; PMCID: PMC4178524.
    59. Tewari KS, Monk BJ. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Clin Cancer Res. 2014 Nov 01; 20(21):5349-58. PMID: 25104084.
      View in: PubMed
    60. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014 Aug; 26(4):314-21. PMID: 24979076.
      View in: PubMed
    61. Miller DS, Blessing JA, Ramondetta LM, Pham HQ, Tewari KS, Landrum LM, Brown J, Mannel RS. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014 Sep 01; 32(25):2744-9. PMID: 25071133; PMCID: PMC4145184.
    62. Monk BJ, Tewari KS. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol. 2014 Sep 01; 32(25):2687-90. PMID: 25071120.
      View in: PubMed
    63. Eskander RN, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol. 2014 Jul; 25(3):249-59. PMID: 25045438; PMCID: PMC4102744.
    64. Eskander RN, Tewari KS. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol. 2014 Sep; 7(5):613-22. PMID: 24984781.
      View in: PubMed
    65. Long B, Eskander RN, Tewari KS. Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review. World J Radiol. 2014 Jun 28; 6(6):366-73. PMID: 24976937; PMCID: PMC4072821.
    66. Eskander RN, Osann K, Dickson E, Holman LL, Rauh-Hain JA, Spoozak L, Wu E, Krill L, Fader AN, Tewari KS. Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study. Gynecol Oncol. 2014 Aug; 134(2):379-84. PMID: 24887355; PMCID: PMC4191825.
    67. Tewari KS. New world order(s): healthcare metrics, international borders, and gravitational waves. Gynecol Oncol. 2014 May; 133(2):139-41. PMID: 24773670.
      View in: PubMed
    68. Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. Gynecol Oncol. 2014 Jun; 133(3):439-45. PMID: 24657300.
      View in: PubMed
    69. Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20; 370(8):734-43. PMID: 24552320; PMCID: PMC4010094.
    70. Eskander RN, Tewari KS. American Society of Clinical Oncology 2013: summary of scientific advancements in gynecologic cancer. Int J Gynecol Cancer. 2014 Jan; 24(1):13-8. PMID: 24300468; PMCID: PMC3907666.
    71. Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014 Feb; 132(2):496-505. PMID: 24316305.
      View in: PubMed
    72. Kalantari M, Osann K, Calleja-Macias IE, Kim S, Yan B, Jordan S, Chase DM, Tewari KS, Bernard HU. Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia. Virology. 2014 Jan 05; 448:314-21. PMID: 24314662; PMCID: PMC4051423.
    73. Eskander RN, Tewari KS. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol. 2013 Oct 03; 5(Suppl 1):55-61. PMID: 24124397; PMCID: PMC3795053.
    74. Bristow RE, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, Tewari KS, Munroe DG, Ueland FR. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J Obstet Gynecol. 2013 Dec; 209(6):581.e1-8. PMID: 23942039.
      View in: PubMed
    75. Brueseke TJ, Tewari KS. Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clin Pharmacol. 2013; 5:13-9. PMID: 23723721; PMCID: PMC3666910.
    76. Eskander RN, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS. Outside slide review in gynecologic oncology: impact on patient care and treatment. Int J Gynecol Pathol. 2013 May; 32(3):293-8. PMID: 23518913.
      View in: PubMed
    77. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun; 129(3):486-94. PMID: 23438670; PMCID: PMC3700732.
    78. Tewari KS. American Society of Clinical Oncology 2012 Annual Meeting: highlights from the gynecologic oncology track. Int J Gynecol Cancer. 2012 Nov; 22(9):1634-9. PMID: 23095779.
      View in: PubMed
    79. Tewari KS. Advanced cytoreductive surgery workshop report. Int J Gynecol Cancer. 2012 Nov; 22(9):1604-10. PMID: 23095776.
      View in: PubMed
    80. Chase DM, Osann K, Sepina N, Wenzel L, Tewari KS. The challenge of follow-up in a low-income colposcopy clinic: characteristics associated with noncompliance in high-risk populations. J Low Genit Tract Dis. 2012 Oct; 16(4):345-51. PMID: 22622340; PMCID: PMC4293035.
    81. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012 Nov; 127(2):345-50. PMID: 22885469; PMCID: PMC3518448.
    82. Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012; 4:395-404. PMID: 22927770; PMCID: PMC3422105.
    83. Pinn-Bingham M, Puthawala AA, Syed AM, Sharma A, Disaia P, Berman M, Tewari KS, Randall-Whitis L, Mahmood U, Ramsinghani N, Kuo J, Chen WP, McLaren CE. Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: long-term results. Int J Radiat Oncol Biol Phys. 2013 Mar 01; 85(3):714-20. PMID: 22763030; PMCID: PMC3842617.
    84. Dellinger TH, Planutis K, Tewari KS, Holcombe RF. Role of canonical Wnt signaling in endometrial carcinogenesis. Expert Rev Anticancer Ther. 2012 Jan; 12(1):51-62. PMID: 22149432.
      View in: PubMed
    85. Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull ML, Monk BJ, Randall ME. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):87-93. PMID: 22155678.
      View in: PubMed
    86. Tewari KS, Monk BJ. American Society of Clinical Oncology 2011 Annual Meeting update: summary of selected gynecologic cancer abstracts. Gynecol Oncol. 2011 Aug; 122(2):209-12. PMID: 21763890.
      View in: PubMed
    87. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Aug; 205(2):103-10. PMID: 21411052.
      View in: PubMed
    88. Chase DM, Mathur N, Tewari KS. Drug discovery in ovarian cancer. Recent Pat Anticancer Drug Discov. 2010 Nov; 5(3):251-60. PMID: 20524931.
      View in: PubMed
    89. Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct; 20(7):1137-41. PMID: 21495215; PMCID: PMC3079178.
    90. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50. PMID: 20846715.
      View in: PubMed
    91. Kalantari M, Chase DM, Tewari KS, Bernard HU. Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: a pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression. J Med Virol. 2010 Feb; 82(2):311-20. PMID: 20029805.
      View in: PubMed
    92. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol. 2010 Feb; 8(2):108-15. PMID: 20386532.
      View in: PubMed
    93. Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR. Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):339-42. PMID: 19772939.
      View in: PubMed
    94. Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie. 2009 Oct; 32(10):552-4. PMID: 19816070.
      View in: PubMed
    95. Mahdavi A, Monk BJ, Ragazzo J, Hunter MI, Lentz SE, Vasilev SA, Tewari KS. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. Int J Gynecol Cancer. 2009 Aug; 19(6):1080-4. PMID: 19820372.
      View in: PubMed
    96. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol. 2009 Apr; 36(2):170-80. PMID: 19332251.
      View in: PubMed
    97. Meltzer SM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol. 2009 Mar; 200(3):233.e1-7. PMID: 19019336.
      View in: PubMed
    98. Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer. Gynecol Oncol. 2009 Jan; 112(1):85-9. PMID: 18977518.
      View in: PubMed
    99. Chan JK, Tewari KS, Waller S, Cheung MK, Shin JY, Osann K, Kapp DS. The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol. 2008 Aug 01; 98(2):111-6. PMID: 18563734; PMCID: PMC4111627.
    100. Hunter MI, Tewari K, Monk BJ. Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. Am J Obstet Gynecol. 2008 Jul; 199(1):10-8. PMID: 18585521.
      View in: PubMed
    101. Hunter MI, Monk BJ, Tewari KS. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. Am J Obstet Gynecol. 2008 Jul; 199(1):3-9. PMID: 18585520.
      View in: PubMed
    102. Chase DM, Monk BJ, Wenzel LB, Tewari KS. Supportive care for women with gynecologic cancers. Expert Rev Anticancer Ther. 2008 Feb; 8(2):227-41. PMID: 18279064.
      View in: PubMed
    103. Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol. 2007 Nov; 107(2 Suppl 1):S6-13. PMID: 18499914.
      View in: PubMed
    104. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007 Jul 10; 25(20):2952-65. PMID: 17617527.
      View in: PubMed
    105. Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005 Nov; 7(6):419-34. PMID: 16221379.
      View in: PubMed
    106. Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol. 2005 Sep; 98(3):360-8. PMID: 16000215.
      View in: PubMed
    107. Geas FL, Tewari DS, Rutgers JK, Tewari KS, Berman ML. Surgical cytoreduction and hormone therapy of an advanced endometrial stromal sarcoma of the ovary. Obstet Gynecol. 2004 May; 103(5 Pt 2):1051-4. PMID: 15121605.
      View in: PubMed
    108. Berg JC, Tewari KS, Del Rosario R, Berman ML. Unusual presentation of a malignant granular cell tumor of the pelvis: case report and literature review. Gynecol Oncol. 2003 Jul; 90(1):224-30. PMID: 12821371.
      View in: PubMed
    109. Tewari KS, DiSaia PJ. Primary prevention of uterine cervix cancer: focus on vaccine history and current strategy. Obstet Gynecol Clin North Am. 2002 Dec; 29(4):843-68, ix. PMID: 12509098.
      View in: PubMed
    110. Syed AM, Puthawala AA, Abdelaziz NN, el-Naggar M, Disaia P, Berman M, Tewari KS, Sharma A, Londrc A, Juwadi S, Cherlow JM, Damore S, Chen YJ. Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2002 Sep 01; 54(1):67-78. PMID: 12182976.
      View in: PubMed
    111. Tewari KS, Disaia PJ. Lung and bronchus cancer in women: a 21st-century epidemic. Clin Obstet Gynecol. 2002 Sep; 45(3):784-811. PMID: 12370622.
      View in: PubMed
    112. Tewari KS, DiSaia PJ. Radiation therapy for gynecologic cancer. J Obstet Gynaecol Res. 2002 Jun; 28(3):123-40. PMID: 12214828.
      View in: PubMed
    113. Monk BJ, Tewari KS, Puthawala AA, Syed AM, Haugen JA, Burger RA. Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys. 2002 Mar 01; 52(3):806-15. PMID: 11849805.
      View in: PubMed